business
This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million
Key takeaways
- According to a SEC filing dated May 15, 2026, High Vista Strategies reduced its stake in Viridian Therapeutics (NASDAQ:VRDN) by 238,243 shares during the first quarter.
- NYSEMKT:DBC: $30.61 million (8.5% of AUM)
- NASDAQ:ABVX: $12.61 million (3.5% of AUM)
Jonathan Ponciano, The Motley Fool Mon, May 18, 2026 at 1:52 AM GMT+7 4 min read VRDN ABVX PRAX COGT SYRE High Vista Strategies reported a sale of 238,243 shares of Viridian Therapeutics (NASDAQ:VRDN) in its May 15, 2026, SEC filing, an estimated $7.08 million trade based on quarterly average pricing.
According to a SEC filing dated May 15, 2026, High Vista Strategies reduced its stake in Viridian Therapeutics (NASDAQ:VRDN) by 238,243 shares during the first quarter. The estimated value of shares sold was about $7.08 million, based on the period s average closing price. After accounting for stock price movements, the quarter-end value of the position declined by $8.97 million.
NYSEMKT:DBC: $30.61 million (8.5% of AUM)
Article preview — originally published by Yahoo Finance. Full story at the source.
Read full story on Yahoo Finance →
More top stories
Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop